Hypertension is one of the most common medical problems in the United States and in the VA
health care system. It has been well-documented that hypertension can be effectively treated.
However, there remain important unresolved clinical questions in the area of antihypertensive
treatment. For example, how much is mortality affected by visit compliance, blood pressure
control and type of antihypertensive agent? Or, are some regimens associated with more
morbidity than others? Or, are there inexpensive regimens that are as effective as more
expensive regimens? The amount of data that is available from this demonstration project
(currently 6,100 patients) will help address these questions. The answers to these questions
should result in better care for veterans with hypertension.
Hypertension is one of the most common medical problems in the United States and in the VA
health care system. It has been well-documented that hypertension can be effectively treated.
However, there remain important unresolved clinical questions in the area of antihypertensive
treatment. For example, how much is mortality affected by visit compliance, blood pressure
control and type of antihypertensive agent? Or, are some regimens associated with more
morbidity than others? Or, are there inexpensive regimens that are as effective as more
expensive regimens? The amount of data that is available from this demonstration project
(currently 6,100 patients) will help address these questions. The answers to these questions
should result in better care for veterans with hypertension.
Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg
Completed
Mylan Pharmaceuticals
Phase 1
2002-12-01
The objective of this study was to investigate the bioequivalence of Mylan metolazone 2.5 mg
tablets to Celltech Zaroxolyn® 2.5 mg tablets following a single, oral 10 mg (4 x 2.5 mg)
dose administration under fasting conditions.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
